SCHEMBL876786

SCHEMBL876786

O=C(O)C=CCC1(c2ccccc2)CCCCC12OCCO2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.36
RXRA P19793 1/20 0.34
RXRG P48443 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 3/20 0.33
HDAC4 P56524 2/20 0.33
TSHR P16473 2/20 0.33
FFAR4 Q5NUL3 1/20 0.33
LMNA P02545 4/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
APOBEC3A P31941 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
POLB P06746 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SIGMAR1 Q99720 2/20 0.32
DRD2 P14416 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL876785 1.00 AKR1C1 (0.36) AKR1C1RXRARXRGSMN1; SMN2ALDH1A1
SCHEMBL461511 0.87 KDM4E (0.36) AKR1C1ALDH1A1HDAC4TSHRHTT
SCHEMBL461510 0.87 KDM4E (0.36) AKR1C1ALDH1A1HDAC4TSHRHTT
SCHEMBL459036 0.82 DPP4 (0.34) AKR1C1SMN1; SMN2TSHRLMNAMEN1
SCHEMBL16986566 0.81 TSHR (0.38) AKR1C1SMN1; SMN2ALDH1A1HDAC4TSHR
SCHEMBL16986564 0.81 TSHR (0.38) AKR1C1SMN1; SMN2ALDH1A1HDAC4TSHR
SCHEMBL459744 0.79 MEN1 (0.38) SMN1; SMN2ALDH1A1TSHRMEN1KMT2A
SCHEMBL460162 0.75 AKR1C1 (0.37) AKR1C1SMN1; SMN2ALDH1A1HDAC4TSHR
SCHEMBL433303 0.73 SLC6A4 (0.50) AKR1C1RXRARXRGSMN1; SMN2ALDH1A1
SCHEMBL433304 0.73 SLC6A4 (0.50) AKR1C1RXRARXRGSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187437-B2 Substituted oxadiazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-17 US disclosed
EP-2595969-B1 Substituted 3-phenyl-1,2,4-oxadiazole compounds BRISTOL MYERS SQUIBB CO (US) 2015-04-22 EP disclosed
US-8822510-B2 Substituted 3-phenyl-1,2,4-Oxadiazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-02 US disclosed
EP-2619190-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS Bristol-Myers Squibb Company (US) 2013-07-31 EP disclosed
US-20130190361-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-25 US disclosed
US-20130158001-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS BRISTOL-MYERS SQUBIB COMPANY 2013-06-20 US disclosed
WO-2012040532-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190361-A1 SUBSTITUTED OXADIAZOLE COMPOUNDS S1PR1, S1PR3, S1PR2 AKR1C1 462/4885RXRA 2228/4885RXRG 1965/4885
US-20130158001-A1 SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS S1PR1, S1PR3, S1PR2 AKR1C1 430/4885RXRA 2157/4885RXRG 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.